INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Big pharmaceutical companies
Back to Newsroom
🏢Organization Dossier

Big pharmaceutical companies

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

8 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech Just now (01:37 PM IST)

Big Pharma’s China Deal Spree Deepens as Latest Tie-Up Could Reach $7.8 Billion

Western drugmakers are accelerating their search for innovation in China as the industry braces for a wave of patent expirations that threatens future revenue. The latest deal, potentially worth up to $7.8 billion, underscores how Chinese biotech has become a critical source of early-stage assets for global pharma giants.

By RDU Global Wire5 min read
Global Health & Biotech15 Oct 2026, 09:30 PM IST

Merck CEO Says Personalized Cancer Vaccine Could Be Made Faster as Pipeline Advances

Merck Chief Executive Robert Davis told CNBC he expects the company’s experimental personalized cancer vaccine to become faster to manufacture over time, signaling a potential shift from early-stage scientific promise toward more scalable production. The comments add fresh attention to a closely watched oncology program that investors view as a possible long-term growth driver for Merck and a broader test case for the commercial viability of personalized cancer immunotherapy.

5 min readRead →
Global Markets & Equities15 Oct 2026, 02:39 PM IST

FDA Moves to Tighten Rare-Disease Drug Reviews as New Leadership Seeks Consistency

The U.S. Food and Drug Administration is advancing a new rare-disease framework that could reshape how experimental treatments are designed, reviewed and approved. The initiative signals a shift toward greater consistency and broader evidentiary standards, a move that may raise the bar for developers while potentially improving regulatory predictability.

6 min readRead →
Markets, IPOs & Wealth14 Oct 2026, 01:46 PM IST

Healthtech’s Next Market Cycle Is Being Built Around Sensors, Bioprinting and Personalized Care

A new wave of healthcare technology is moving from experimental promise to commercial relevance, with sensors, wearables, 3D-printed skin, reconstructed organs and data-driven clinical trials reshaping the investment case. For markets and IPO watchers, the shift signals a broader re-rating of healthtech as companies target faster diagnostics, lower trial costs and more individualized treatment pathways.

5 min readRead →
Frontier AI & Machine Learning14 Oct 2026, 01:22 AM IST

GLP-1 Weight-Loss Drugs Show Early Signs of Slowing Biological Aging, But Side Effects Remain Unclear

New research presented at an aging conference in Boston suggests GLP-1 weight-loss drugs may do more than reduce body weight and blood sugar: they may also be associated with a younger biological age in some patients. The findings add to the growing scientific and commercial momentum behind the drugs, while underscoring how much remains unknown about their long-term effects, trade-offs, and safety profile.

5 min readRead →
Big Tech, Cloud & Semiconductors12 Oct 2026, 05:27 PM IST

NASA Opens Door to Private Space Stations as ISS Era Winds Down

NASA has issued a long-awaited call to industry for private space stations, accelerating a transition that could reshape the economics of low Earth orbit and the future of U.S. human spaceflight. The agency says it intends to remain a permanent presence in orbit even as it shifts from owning and operating the International Space Station to buying services from commercial providers.

6 min readRead →
Big Tech, Cloud & Semiconductors11 Oct 2026, 05:28 AM IST

NASA Opens Door to Private Space Stations as Low Earth Orbit Transition Accelerates

NASA has issued a long-awaited solicitation to industry for privately built space stations, marking a pivotal step in the agency’s plan to sustain a continuous human presence in low Earth orbit after the International Space Station era. The move signals a broader shift from government-operated infrastructure toward commercially owned orbital platforms, with major implications for aerospace contractors, cloud-linked space services, and the semiconductor supply chain that underpins advanced space hardware.

5 min readRead →
Global Health & Biotech04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With China’s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmaker’s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

6 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Big pharmaceutical companies: